Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jan;39(1):137–144. doi: 10.1128/aac.39.1.137

Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine.

E Schoondermark-van de Ven 1, J Galama 1, T Vree 1, W Camps 1, I Baars 1, T Eskes 1, J Meuwissen 1, W Melchers 1
PMCID: PMC162499  PMID: 7695295

Abstract

The efficacy of the combination of pyrimethamine and sulfadiazine for the treatment of congenital Toxoplasma gondii infection in rhesus monkeys was studied. The dosage regimen for pyrimethamine and sulfadiazine was established by pharmacokinetic studies in two monkeys. Those studies showed that the distributions of both drugs followed a one-compartment model. The serum elimination half-lives were found to be 5.2 h for sulfadiazine and 44.4 h for pyrimethamine. Sulfadiazine reached a maximum concentration in serum of 58.7 micrograms/ml, whereas a maximum concentration in serum of 0.22 micrograms/ml was found for pyrimethamine. Ten monkeys were infected intravenously with T. gondii at day 90 of pregnancy, which is comparable to the second trimester of organogenetic development in humans. Treatment was administered to six monkeys, in whose fetuses infection was diagnosed antenatally. From the moment that fetal infection was proven, the monkeys were treated throughout pregnancy with 1 mg of pyrimethamine per kg of body weight per day and 50 mg of sulfadiazine per kg of body weight per day orally. The therapy was supplemented with 3.5 mg of folinic acid once a week. No toxic side effects were found with this drug regimen. The parasite was no longer detectable in the next consecutive amniotic fluid sample, taken 10 to 13 days after treatment was started. Furthermore, T. gondii was also not found in the neonate at birth. The parasite was still present at birth in three of four untreated fetuses that served as controls. Both drugs crossed the placenta very well. Concentrations in fetal serum varied from 0.05 to 0.14 micrograms/ml for pyrimethamine and from 1.0 to 5.4 micrograms/ml for sulfadiazine. In addition, pyrimethamine was found to accumulate in the brain tissue, with concentrations being three to four times higher than the corresponding concentrations in serum. Thirty percent of the sulfadiazine was found to reach the brain tissue when compared with the corresponding serum concentration. when administered early after the onset of infection, the combination of pyrimethamine and sulfadiazine was clearly effective in reducing the number of parasites in the fetus to undetectable levels.

Full Text

The Full Text of this article is available as a PDF (234.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albert F., Bishop-Freudling G. B., Vergin H. Diffusion von Tetroxoprim und Sulfadiazin in den Liquor cerebrospinalis bei neurochirurgischen Patienten. Fortschr Med. 1984 Nov 8;102(41):1064–1066. [PubMed] [Google Scholar]
  2. Andreasen F., Elsborg L., Husted S., Thomsen O. Pharmacokinetics of sulfadiazine and trimethoprim in man. Eur J Clin Pharmacol. 1978 Nov 9;14(1):57–67. doi: 10.1007/BF00560259. [DOI] [PubMed] [Google Scholar]
  3. Araujo F. G., Huskinson-Mark J., Gutteridge W. E., Remington J. S. In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob Agents Chemother. 1992 Feb;36(2):326–330. doi: 10.1128/aac.36.2.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Araujo F. G., Lin T., Remington J. S. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine. J Infect Dis. 1993 Feb;167(2):494–497. doi: 10.1093/infdis/167.2.494. [DOI] [PubMed] [Google Scholar]
  5. Boom R., Sol C. J., Salimans M. M., Jansen C. L., Wertheim-van Dillen P. M., van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol. 1990 Mar;28(3):495–503. doi: 10.1128/jcm.28.3.495-503.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Boulot P., Pratlong F., Sarda P., Deschamps F., Hedon B., Laffargue F., Viala J. L. Limites du traitement prénatal de la toxoplasmose congénitale par l'association sulfadiazine-pyriméthamine. Presse Med. 1990 Mar 31;19(12):570–570. [PubMed] [Google Scholar]
  7. Cavallito J. C., Nichol C. A., Brenckman W. D., Jr, Deangelis R. L., Stickney D. R., Simmons W. S., Sigel C. W. Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man. Drug Metab Dispos. 1978 May-Jun;6(3):329–337. [PubMed] [Google Scholar]
  8. Couvreur J. Le traitement in utero de la toxoplasmose congénitale par l'association pyriméthamine-sulfadiazine. Presse Med. 1991 Jun 22;20(24):1136–1136. [PubMed] [Google Scholar]
  9. Couvreur J., Thulliez P., Daffos F., Aufrant C., Bompard Y., Gesquière A., Desmonts G. In utero treatment of toxoplasmic fetopathy with the combination pyrimethamine-sulfadiazine. Fetal Diagn Ther. 1993 Jan-Feb;8(1):45–50. doi: 10.1159/000263746. [DOI] [PubMed] [Google Scholar]
  10. Daffos F., Forestier F., Capella-Pavlovsky M., Thulliez P., Aufrant C., Valenti D., Cox W. L. Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. N Engl J Med. 1988 Feb 4;318(5):271–275. doi: 10.1056/NEJM198802043180502. [DOI] [PubMed] [Google Scholar]
  11. Derouin F., Chastang C. In vitro effects of folate inhibitors on Toxoplasma gondii. Antimicrob Agents Chemother. 1989 Oct;33(10):1753–1759. doi: 10.1128/aac.33.10.1753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dorangeon P., Fay R., Marx-Chemla C., Leroux B., Harika G., Dupouy D., Quereux C., Choisy H., Pinon J. M., Wahl P. Passage transplacentaire de l'association pyriméthamine-sulfadoxine lors du traitement anténatal de la toxoplasmose congénitale. Presse Med. 1990 Dec 22;19(44):2036–2036. [PubMed] [Google Scholar]
  13. Friis C., Gyrd-Hansen N., Nielsen P., Olsen C. E., Rasmussen F. Pharmacokinetics and metabolism of sulphadiazine in neonatal and young pigs. Acta Pharmacol Toxicol (Copenh) 1984 May;54(5):321–326. doi: 10.1111/j.1600-0773.1984.tb01937.x. [DOI] [PubMed] [Google Scholar]
  14. Goodman N. W. Anaesthetic research: new approaches need fresh attitudes. Anaesthesia. 1990 Nov;45(11):985–987. doi: 10.1111/j.1365-2044.1990.tb14643.x. [DOI] [PubMed] [Google Scholar]
  15. Harper J. S., 3rd, London W. T., Sever J. L. Five drug regimens for treatment of acute toxoplasmosis in squirrel monkeys. Am J Trop Med Hyg. 1985 Jan;34(1):50–57. doi: 10.4269/ajtmh.1985.34.50. [DOI] [PubMed] [Google Scholar]
  16. Hayama T., Kokue E. Use of the Goettingen miniature pig for studying pyrimethamine teratogenesis. Crit Rev Toxicol. 1985;14(4):403–421. doi: 10.3109/10408448509037463. [DOI] [PubMed] [Google Scholar]
  17. Hohlfeld P., Daffos F., Thulliez P., Aufrant C., Couvreur J., MacAleese J., Descombey D., Forestier F. Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. J Pediatr. 1989 Nov;115(5 Pt 1):765–769. doi: 10.1016/s0022-3476(89)80660-2. [DOI] [PubMed] [Google Scholar]
  18. Horvath C., Tangapregassom A. M., Tangapregassom M. J., Trecul M., Boucher-Ehrensperger M., Compagnon A., Petter C. Pathogenesis of limb and facial malformations induced by pyrimethamine in the rat. Acta Morphol Hung. 1988;36(1-2):53–61. [PubMed] [Google Scholar]
  19. Koppe J. G., Loewer-Sieger D. H., de Roever-Bonnet H. Results of 20-year follow-up of congenital toxoplasmosis. Lancet. 1986 Feb 1;1(8475):254–256. doi: 10.1016/s0140-6736(86)90785-3. [DOI] [PubMed] [Google Scholar]
  20. Leport C., Meulemans A., Robine D., Dameron G., Vildé J. L. Levels of pyrimethamine in serum and penetration into brain tissue in humans. AIDS. 1992 Sep;6(9):1040–1041. doi: 10.1097/00002030-199209000-00021. [DOI] [PubMed] [Google Scholar]
  21. Mack D. G., McLeod R. New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. Antimicrob Agents Chemother. 1984 Jul;26(1):26–30. doi: 10.1128/aac.26.1.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mansor S. M., Navaratnam V., Mohamad M., Hussein S., Kumar A., Jamaludin A., Wernsdorfer W. H. Single dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers. Br J Clin Pharmacol. 1989 Mar;27(3):381–386. doi: 10.1111/j.1365-2125.1989.tb05381.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. McLeod R., Mack D., Foss R., Boyer K., Withers S., Levin S., Hubbell J. Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group. Antimicrob Agents Chemother. 1992 May;36(5):1040–1048. doi: 10.1128/aac.36.5.1040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Männistö P., Tuomisto J., Saris N. E., Lehtinen T. Pharmacokinetic studies with trimethoprim and different doses of sulfadiazine in healthy human subjects. Chemotherapy. 1973;19(5):289–298. doi: 10.1159/000221467. [DOI] [PubMed] [Google Scholar]
  25. Nain C. K., Sharma B., Mehta S. Disposition of sulphadiazine in rhesus monkeys. Indian J Exp Biol. 1982 Jan;20(1):70–73. [PubMed] [Google Scholar]
  26. Nehru B., Mehta S., Nain C. K., Mathur V. S. Disposition of sulphadiazine in young rhesus monkeys with protein calorie malnutrition. Int J Clin Pharmacol Ther Toxicol. 1988 Oct;26(10):509–512. [PubMed] [Google Scholar]
  27. Nguyen B. T., Stadtsbaeder S. Comparative effects of cotrimoxazole (trimethoprim-sulphamethoxazole), pyrimethamine-sulphadiazine and spiramycin during avirulent infection with Toxoplasma gondii (Beverley strain) in mice. Br J Pharmacol. 1983 Aug;79(4):923–928. doi: 10.1111/j.1476-5381.1983.tb10537.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Piketty C., Derouin F., Rouveix B., Pocidalo J. J. In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice. Antimicrob Agents Chemother. 1990 Aug;34(8):1467–1472. doi: 10.1128/aac.34.8.1467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Proost J. H., Meijer D. K. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med. 1992 May;22(3):155–163. doi: 10.1016/0010-4825(92)90011-b. [DOI] [PubMed] [Google Scholar]
  30. Reeves D. S., Broughall J. M., Bywater M. J., Holt H. A., Vergin H. Pharmacokinetics of tetroxoprim and sulphadiazine in human volunteers. J Antimicrob Chemother. 1979 Nov;5(B):119–138. doi: 10.1093/jac/5.supplement_b.119. [DOI] [PubMed] [Google Scholar]
  31. SCHMIDT L. H., HUGHES H. B., SCHMIDT I. G. The pharmacological properties of 2, 4-diamino-5-p-chlorophenyl-6-ethylpyrimidine, daraprim. J Pharmacol Exp Ther. 1953 Jan;107(1):92–130. [PubMed] [Google Scholar]
  32. Schoondermark-Van de Ven E., Melchers W., Camps W., Eskes T., Meuwissen J., Galama J. Effectiveness of spiramycin for treatment of congenital Toxoplasma gondii infection in rhesus monkeys. Antimicrob Agents Chemother. 1994 Sep;38(9):1930–1936. doi: 10.1128/aac.38.9.1930. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Schoondermark-Van de Ven E., Melchers W., Galama J., Camps W., Eskes T., Meuwissen J. Congenital toxoplasmosis: an experimental study in rhesus monkeys for transmission and prenatal diagnosis. Exp Parasitol. 1993 Sep;77(2):200–211. doi: 10.1006/expr.1993.1077. [DOI] [PubMed] [Google Scholar]
  34. Sheffield H. G., Melton M. L. Effect of pyrimethamine and sulfadiazine on the fine structure and multiplication of Toxoplasma gondii in cell cultures. J Parasitol. 1975 Aug;61(4):704–712. [PubMed] [Google Scholar]
  35. Tangapregassom A. M., Tangapregassom M. J., Horvath C., Trecul M., Boucher-Ehrensperger M., Petter C. Vascular anomalies and pyrimethamine-induced malformations in the rat. Teratog Carcinog Mutagen. 1985;5(1):55–62. doi: 10.1002/tcm.1770050107. [DOI] [PubMed] [Google Scholar]
  36. Vergin H., Bishop-Freudling G. B., Foing N., Szelenyi I., Armengaud H., van Tho T. Diffusion of metioprim, tetroxoprim and sulphadiazine in the cerebrospinal fluid of dogs with healthy meninges and dogs with experimental meningitis. Chemotherapy. 1984;30(5):297–304. doi: 10.1159/000238284. [DOI] [PubMed] [Google Scholar]
  37. Weiss L. M., Luft B. J., Tanowitz H. B., Wittner M. Pyrimethamine concentrations in serum during treatment of acute murine experimental toxoplasmosis. Am J Trop Med Hyg. 1992 Mar;46(3):288–291. doi: 10.4269/ajtmh.1992.46.288. [DOI] [PubMed] [Google Scholar]
  38. van de Ven E., Melchers W., Galama J., Camps W., Meuwissen J. Identification of Toxoplasma gondii infections by BI gene amplification. J Clin Microbiol. 1991 Oct;29(10):2120–2124. doi: 10.1128/jcm.29.10.2120-2124.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES